SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology.
SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most.
SPIMA Therapeutics is part of the nexus of Landmark Bioventures.
Join us in shaping the future of medicine, where discovery meets dedication.
Company Details
- Employees
- 3
- Founded
- 2024
- Address
- 80, Avenue Augustin Fliche, Incubateur Cyborg – Irmb,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Immunothery.
- HQ
- Montpellier, Occitanie, France
Spima Therapeutics Questions
Spima Therapeutics's website is https://www.spima-therapeutics.com/
Spima Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/spima-therapeutics
Spima Therapeutics has
3 employees.
View email and phone details for 3
employees at Spima Therapeutics.
Spima Therapeutics's industry is
Biotechnology Research
Spima Therapeutics's top competitors are
Carla Biotherapeutics,
Kekkan Biologics,
Elikya Therapeutics,
Landmark Bioventures Ag,
Bioexpert Network,
Azurbio Pharma,
Innovative Diagnostics,
Pharmaceutical Innovation Advisory-Fze,
Scirosbio,
Satt Axlr.
Spima Therapeutics's categories are Biotechnology Research
Spima Therapeutics's founding year is 2024
